Articles tagged with Sepsis
Researchers developed a ground-breaking method to detect sepsis 2-3 days before clinical symptoms appear using endogenous signals (biomarkers). The test has high accuracy and may increase survival chances for sepsis patients. Approval in the US FDA is underway, with clinical trials starting soon.
Rates of E. coli-related sepsis vary greatly between UK NHS regions and are linked to the presence of pathogenic E. coli types in sewage. The study found higher prevalence of E. coli B2 types in South Wales, which correlates with higher sepsis rates.
Researchers have developed an antibody treatment that improves survival in rodent models of sepsis by targeting a protein called tetranectin. The therapy boosts survival even when started late after sepsis onset, suggesting its potential for treating severe bacterial infections and secondary sepsis in COVID-19 patients.
A study of 13,000 urgent GP referrals found that higher early warning scores are associated with quicker ambulance transfers and faster hospital reviews. Patients with the highest scores were nearly five times more likely to have sepsis and eight times more likely to die within two days of admission.
Researchers propose a new therapeutic modality for sepsis by targeting cell-free chromatin in healthy cells. The study found that three cfCh-inactivating agents improved parameters related to sepsis, including increased survival rates in mice.
Researchers have identified two crucial surface proteins, SpyAD and Isp2, that contribute to Group A streptococcus fitness in the female genital tract. This discovery may lead to the development of effective treatments and vaccines for puerperal sepsis.
Researchers found that breast milk with higher levels of epidermal growth factor can activate intestinal cells to keep harmful gut bacteria from migrating into the bloodstream. This could provide a potential new tool to combat late-onset sepsis in premature babies.
A new next-generation sequencing technique using real-time nanopore sequencing can analyze tiny amounts of microbial cell-free DNA, offering accurate diagnosis of sepsis-causing agents within hours. The technique achieved a 3.5-fold increase in sequencing throughput and allowed for pathogen identification within minutes.
Researchers developed a novel treatment that compacts and stabilizes neutrophil extracellular traps (NETs) to enhance bacterial capture, resist degradation, and improve sepsis outcomes. The treatment improved survival in mice with sepsis by reducing severity of illness and decreasing bacteria levels.
Researchers developed a novel computational algorithm to track pediatric sepsis epidemiology, providing more accurate data on outcomes and incidence over time. The algorithm showed an increasing incidence of sepsis among hospital encounters and mortality rates remained stable.
A new portable biosensor developed by researchers at EPFL's School of Engineering can rapidly detect sepsis biomarkers in a patient's bloodstream, slashing diagnosis time from several days to just a few minutes. The device uses plasmonics technology and achieves accuracy on par with gold-standard laboratory methods.
A new study published in The Lancet reveals sepsis is responsible for an estimated 48.9 million global cases and 11 million deaths in 2017, representing a doubling of previous estimates.
Scientists at Ohio State University have created a treatment for late-stage sepsis using nanotechnology to transform donated immune cells into a powerful antibacterial drug. The therapy demonstrated significant improvements in survival rates and bacteria clearance in mouse models of sepsis.
Researchers found that energy-producing mitochondria in muscles were abnormal and showed signs of oxidative damage, contributing to chronic muscle weakness. The study suggests the need for antioxidant therapies or other treatments to restore mitochondrial health.
A national approach for pediatric sepsis surveillance has been developed, utilizing electronic health records to facilitate widespread tracking of rates and outcomes. The proposed approach includes a preliminary case definition adapted to address specific differences among infants and children.
A digital alert system has been introduced to monitor patients with sepsis, leading to lower odds of death and shorter hospital stays. The system has also increased the chances of receiving timely antibiotics, resulting in improved outcomes for patients.
Biomedical researchers at Cincinnati Children's Hospital Medical Center have developed a new rapid blood assay called PERSEVERE to detect and stratify sepsis. The test accurately predicts patient risk of death from sepsis, enabling early medical interventions with greater precision.
Researchers have developed a new way to measure white blood cell function, providing more accurate prognostic information for patients with sepsis. The technology assesses activation state and function of white blood cells from small blood samples, allowing for earlier diagnosis and treatment.
Dr. Judith Hellman has been awarded the American Society of Anesthesiologists' Excellence in Research Award for her groundbreaking research on sepsis and inflammatory critical illness. Her discoveries have led to improved understanding of inflammation, immune function, and potential treatments for sepsis.
A new rapid testing method is being used to improve antibiotic treatment for sepsis patients, enabling medical teams to make quicker and more targeted therapy choices. The study found that providing rapid drug susceptibility information can lead to better patient outcomes and less unnecessary broad-spectrum antibiotic use.
Researchers identified specific microRNAs that predict pneumonia complications, enabling early detection and intervention. The study found correlations between microRNA profiles and sepsis and respiratory failure in pneumonia patients.
A randomized clinical trial found that high-dose intravenous vitamin C did not reduce organ failure, inflammation, or vascular injury in patients with sepsis and acute respiratory distress syndrome (ARDS). The study's limitations include underpowered detection of differences and insufficient dosage.
A new study published in JAMA found that treating septic patients with intravenous vitamin C infusions significantly reduced mortality and improved recovery times. The trial showed a 30% reduction in mortality at day 28 compared to the placebo group, and patients spent three fewer days in the ICU.
A new study finds that drawing blood cultures after starting antimicrobial treatment can result in a significant loss of available clinical information. The study suggests that drawing blood cultures prior to treatment may be more effective in identifying the bacteria causing the infection and selecting the right antibiotic.
A new study has found that initiating antibiotics immediately before obtaining blood cultures significantly affects their sensitivity and ability to diagnose bacterial and fungal infections. This change in guidelines may reduce mortality rates from sepsis, a life-threatening condition with a 20% mortality rate.
A recent study published in Annals of Internal Medicine found that early blood sampling for microorganisms is critical to treating sepsis. Emergency rooms must follow sepsis guidelines, which demand trained personnel and proper equipment, to prevent organ damage and death.
A $40,000 grant from The Emergency Medicine Foundation is supporting a study to increase awareness among parents about sepsis signs in children. Researchers hope this will lead to improved recognition strategies and faster diagnosis of sepsis.
Researchers found that sevoflurane improved survival rates and reduced bacterial presence in organs of mice with induced sepsis compared to isoflurane or no anesthetic. The study suggests a critical role for the type of general anesthesia used in treating sepsis.
Researchers found altered gut microbiota in sepsis patients, leading to more severe liver damage in mice. The study suggests that transplantation of healthy feces may help treat sepsis in intensive care units.
Researchers investigated metabolic changes across organs in a large animal model of sepsis, identifying common and organ-specific alterations that could inform new therapeutic approaches. The study, published in The American Journal of Pathology, has the potential to reduce mortality and morbidity associated with sepsis.
Researchers at University of California San Diego School of Medicine found that removing the enzyme PHLPP1 improves outcomes in a mouse model of sepsis. The study introduces the possibility of inhibiting PHLPP1 as a new treatment for sepsis.
Sepsis survivors are at higher risk for major health problems and death due to persistent inflammation, according to a study published in JAMA Network Open. The researchers found that nearly all patients with sepsis have increased inflammation during hospitalization, but this inflammation often persists long after discharge.
A national study found that combining early home health nursing with at least one outpatient physician visit after hospital discharge reduces the risk of 30-day hospital readmission for sepsis patients. The intervention facilitates coordinated care planning and early surveillance, resulting in improved outcomes.
Scientists at WashU Medicine have found a set of genes that help cells survive exposure to cytokines, which can trigger a deadly cytokine storm. Targeting these genes may lead to new treatments for sepsis, a life-threatening condition that claims 15% of patients despite prompt medical care.
A study led by University of Pittsburgh researchers found that implementing a state-mandated sepsis regulation in New York resulted in a significant drop in death rates from sepsis, with a 4.3% decrease compared to control states. The policy requires hospitals to quickly implement certain protocols when sepsis is suspected.
State-mandated protocols for sepsis care in New York have been associated with significant improvements in patient outcomes, including a reduced risk of death. The study analyzed hospital discharge data and found that these regulations led to better management of sepsis cases, resulting in improved survival rates.
A new study found that while the New York Sepsis Initiative improved overall sepsis care, hospitals treating mainly white patients saw greater increases in protocol compliance than those serving more black patients. This disparity raises concerns about the potential exacerbation of racial disparities in healthcare.
A multicentre study analyzed over 1.9 million pediatric emergency department visits and found no significant association between overcrowding and death within 14 days or hospital admission within 7 days. However, the study saw an increase in admissions among sicker children and return visits from less sick kids with increasing crowding.
A new study found that delayed antibiotic delivery for sepsis patients is associated with lower ER triage scores, particularly among those assigned mid-range scores. This delay can result in longer door-to-antibiotic times of up to 32 minutes, impacting patient survival.
Researchers used big data to identify four distinct subtypes of sepsis, each with unique clinical characteristics and treatment needs. These findings could lead to the development of precision medicine approaches for sepsis treatment, potentially improving patient outcomes.
Researchers have discovered a biochemical compound responsible for the rapid decline in blood pressure during sepsis. The compound, cis-WOOH, is formed by an enzyme and plays a signaling role in vasodilation, potentially leading to organ failure and death.
Scientists have discovered that bacterial proteins and endotoxin activate the inflammasome, leading to pyroptosis and the release of tissue factor, which initiates blood clotting. This understanding may lead to new treatments for sepsis by targeting inflammatory responses.
A KAIST research team visualized pulmonary microcirculation in vivo using a custom-built 3D intravital microscope imaging system. They found that neutrophils aggregate inside capillaries during sepsis-induced acute lung injury, leading to tissue hypoxia and damage.
A new computer-aided model developed in the UK can predict sepsis risk using routinely collected data. The cNEWS score can trigger screening within 30 minutes of admission and support clinical judgment.
The Society for Maternal-Fetal Medicine has released new guidelines for diagnosing and treating sepsis in pregnancy, emphasizing the importance of early recognition and management. The recommendations are designed to improve care and prevent organ damage caused by sepsis, with a focus on increasing maternal survival rates.
Researchers will compare DNA from sepsis patients who died and survived to isolate signals and identify future drug targets. The study, funded by Sepsis Research, aims to better understand how genes govern sepsis recovery.
A study published in JAMA Network Open found that sepsis was present in over 50% of terminal hospitalizations and accounted for 35% of all deaths. However, only one in twenty-five sepsis-associated deaths were considered moderately or highly likely preventable.
A pre-clinical trial of InnovoSep has demonstrated potential to stop sepsis-causing bacteria from triggering organ damage. The drug also showed effectiveness in preventing sepsis progression and treating advanced sepsis.
A recent grant will allow researcher Wendy Walker to study immune cell contributions to sepsis, a life-threatening disorder with a high mortality rate. Her goal is to manipulate these cells to improve clinical outcomes and potentially cure the disease.
Researchers found that delaying or withholding antibiotics for older adults with urinary tract infections increases the risk of bloodstream infections and death. Immediate antibiotic treatment is recommended for this vulnerable group due to their increased susceptibility to sepsis following UTI.
Researchers found that early antibiotic treatment for elderly patients with urinary tract infections (UTIs) reduces the risk of sepsis and death compared to delayed or no treatment. The study suggests that immediate antibiotics should be prescribed for elderly patients with UTIs, especially older men and those living in deprived areas.
Scientists at the University of British Columbia have discovered a new protein 'switch' that can stop the progression of sepsis, a life-threatening disease. This discovery could lead to new treatments for chronic and acute inflammatory diseases.
Sepsis-associated deaths occurred in over half of hospitalizations, with most deaths attributed to complex patients with severe coexisting conditions. Further innovations in prevention and care of underlying conditions may be necessary to reduce sepsis deaths
A study from the University of Virginia Health System suggests that an antidepressant drug could stop deadly sepsis by regulating inflammation. The researchers tested the drug in a mouse model and found it to be effective, paving the way for potential human trials.
A Western diet characterized by low fiber and high fat and sugar content can lead to increased chronic inflammation, higher mortality rates, and more severe sepsis severity in mice. The study identifies molecular markers that could predict patients at high risk for severe sepsis or require aggressive treatment.
Researchers have successfully engineered a protein that balances an overreaction of the immune system, making it a promising candidate for sepsis therapy. By understanding how interleukins mediate communication between immune cells, scientists can now modulate their reaction in a targeted manner.
A synthetic compound derived from flaxseed has been shown to reverse cardiovascular dysfunction and improve heart function in mice with sepsis. Treatment with the antioxidant LGM2605 significantly reduced oxidative stress and restored energy production in heart cells.
Basophils, a rare type of white blood cell, have been found to play a crucial role in preventing sepsis. By releasing protein tumor necrosis factor (TNF), basophils trigger an immune response that helps protect against infection and prevents the progression to sepsis.
A large clinical study in Australia and New Zealand aims to better understand sepsis treatment practices and evaluate the effectiveness of a reduced fluid approach. The study, funded by the Emergency Medicine Foundation, will investigate how intravenous fluids are used to treat sepsis patients.
In a breakthrough study, researchers successfully delivered a microRNA called miR-126 via a nanocarrier to improve survival rates in a preclinical model of sepsis. The treatment resulted in over 67% of mice being alive at seven days compared to just 25% of untreated mice.